RxDoctor Payments Data

Susan Dumire

Nurse Practitioner · Cary, NCNPI 1285230169

Payments from drug & device makers

$4,747in general payments, 2019–2025

Across 204 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Neurocrine Biosciences, Inc.$938
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$893
  • Alkermes, Inc.$551
  • Otsuka America Pharmaceutical, Inc.$330
  • Vanda Pharmaceuticals Inc.$233
  • plus $716 from 12 others

What the payments were for

  • Food & beverage$4,735100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,747 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$18,673
Medicare patients
23
Services billed
197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine28$1,122
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$892
Bupropion XlBupropion Hcl34$737
Quetiapine Fumarate22$612
Desvenlafaxine Succinate ErDesvenlafaxine Succinate14$560
Sertraline Hcl20$461
Mirtazapine19$414
Aripiprazole16$393
Escitalopram Oxalate29$361
Gabapentin27$330
Trazodone Hcl21$187
Paroxetine Hcl11$180
Alprazolam31$176
Clonazepam20$102
Diazepam14$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$53$46120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →